NVTA - Why Is Genetic Testing Invitae Stock Trading Higher Today? | Benzinga
Friday, the FDA granted de novo approval for Invitae Corporation's (NYSE: NVTA) Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect hundreds of genetic variants associated with an elevated risk of developing certain cancers.
The test can also help identify cancer-associated hereditary variants in individuals with already-diagnosed cancer.
The test, the first to be granted FDA marketing authorization, evaluates DNA extracted from ...